DX Fall Obesity Summit 2021

Date: October 14-16, 2021
Accreditation: 12 CME/CE
Thursday, October 14 – 11:00 AM-4:00 PM EST
Friday, October 15 – 11:00 AM-4:00 PM EST
Saturday, October 16 – 10:00 AM-3:00 PM EST

The theme for the DX Fall Obesity Summit 2021 is Treat Obesity Across the Lifespan. Obesity is a diagnosis that is applied broadly, yet the disease of obesity is not the same in all populations. Age, gender, and socioeconomic status are among the many variables that influence obesity treatment.

During the DX Fall Obesity Summit, receive advanced training on treating obesity in different populations and personalizing obesity treatment for each patient, including those who present with complex adiposity-related diseases. Discover existing and new medications that are currently or soon to become available for the treatment of obesity and obesity-related conditions. Understand how to choose and implement an individualized nutritional plan and the impact of various dietary interventions may on weight loss and diseases associated with obesity. Learn about how obesity affects a patient across their lifespan, and discover the latest innovations in the field of obesity medicine.

Schedule on Thursday, Oct. 14

All times displayed in Eastern Time (EST)

  • 11:00 AM-12:00 PM - Keynote Speaker: Paul Long

    Connecting The Workplace And Life Through F.U.N.

    Paul Long

    Organizations around the globe are challenged right now to create meaningful and memorable experiences in a society that feels somewhat disconnected. Speaker, author, podcaster and master of shenanigans, Paul Long leverages his concept of "Fundamism" to deliver a FUN keynote that will provide attendees with practical takeaways to improve mindset and interactions with others.

    Paul's message will lead you through a wealth of emotions as you laugh, think, and have FUN as a team. Through his FUNdamentals, Paul will empower you to make strides in improving your quality of life at home and work. When applied, these tactical behaviors are proven to create more joy, FUN and fulfillment in life while improving key performance indicators like customer experience, employee engagement, performance and a whole host of others.

    At a time where society appears to be more focused on what's not working as opposed to what is, embrace the opportunity to experience "what's GOOD!”

    Learning Objectives:

    1. Identify ways to substantially reduce fear of judgement, anxiety, discomfort and negative self-talk.
    2. Learn how to create meaningful interactions by showcasing a genuine interest in people, connecting at a human level, understanding the needs of others and meeting individuals where they desire to be met.
    3. Establish next steps in manifesting GOOD energy, great relationships, improved business results and an enhanced quality of life by reigniting your childlike exuberance.
  • 12:00-1:00 PM - Obesity Pharmacotherapy: Challenges & Barriers Using Anti-Obesity Medications

    Obesity Pharmacotherapy: Challenges & Barriers Using Anti-Obesity Medications

    Ania Jastreboff, MD, PhD

    One in five adolescents in the Unites States have obesity. The presentation will review currently available anti-obesity medications for the treatment of adolescents with obesity, key concepts in using these medications, as well as considerations for future therapeutics.

    Learning Objectives:

    1. Describe the available anti-obesity medications for the treatment of adolescents with obesity.
    2. Understand key concepts in using anti-obesity medications for the treatment.
    3. Gain insight into considerations for future therapeutics for obesity treatment.
  • 1:00-2:00 PM - Exhibit Hall Break

    Visit the exhibitors and explore the latest technologies, products, and services available to enhance and improve your practice. Meet with exhibitors, try samples, and discover new tools to use when treating patients with obesity.

  • 2:00-3:00 PM - Strategies for Treating Binge Eating Disorder and Loss-of-Control Eating

    Strategies for Treating Binge Eating Disorder and Loss-of-Control Eating

    Kelly Martens, PhD

    This session will provide an overview of binge eating and its impact on weight outcomes, teach attendees how to assess for binge eating and to differentiate between binge eating and other problematic eating behaviors, and provide practical strategies for treating binge eating disorder including evidenced-based behavioral treatment and pharmacotherapy. Attendees will learn how to approach binge eating from a cognitive-behavioral perspective, and when to refer for more intensive intervention

    Learning Objectives:

    1. Define and describe binge-eating disorder (BED) versus other problematic eating behaviors and disorders
    2. Describe the impact of BED
    3. Apply evidenced-based treatment for BED
    4. Discuss practical strategies for any clinician:
      –Assessing for binge eating and triggers
      –Brief intervention and referral for treatment
  • 3:00-4:00 PM - The "Evidence-based" vs. "Internet-based" Keto Diet

    The "Evidence-based" vs. "Internet-based" Keto Diet

    Eric Westman, MD, MHS

    Clinical research into low-carbohydrate, ketogenic diets over the past 20 years have shown repeatedly that a food-based well-formulated, ketogenic diet can be safe and effective for the treatment of obesity and diabetes. In the past few years, the internet has exploded with information about the keto diet with emphasis on sales of keto products. A brief update on clinical research about keto diets, and a survey of “internet keto” diet users will be presented.

    Learning Objectives:

    1. Identify the components of a well-formulated, real food based, ketogenic diet
    2. Discuss the clinical studies supporting the use of a well-formulated ketogenic diet
    3. Name 3 “great for keto diet” products that have not been clinically tested

Schedule on Friday, Oct. 15

All times displayed in Eastern Time (EST)

  • 11:00-11:45 AM - Fatty Liver on Imaging: The Ultimate Incidentaloma?

    Silvana Pannain, MD, Angela Fitch, MD, ABOM, and Scott Butsch, MD, MSc, FTOS, DABOM

    This lecture will discuss the evaluation and management of nonalcoholic fatty liver disease (NAFLD) in a case-based format. The role of insulin resistance in the pathogenesis of the disease will be briefly reviewed in addition to associated co-morbidities. The evaluation of a patient with suspected NAFLD will be discussed, including ruling out other causes of fatty liver, addressing metabolic co-morbidities, and risk stratification NAFLD (i.e assessing for advanced fibrosis). Treatment strategies focused on liver health will also be addressed including the role of lifestyle and weight loss, medications (including metformin, pioglitazone, vitamin E, and emerging roles of semaglutide), and the utility of bariatric surgery. The session will also cover when it would be appropriate to refer to a specialist."

    Learning Objectives:

    1. Identify the key role insulin resistance has on the development of NAFLD
    2. Evaluate patients with NAFLD with practical tools that will allow to risk stratify their liver disease and know when to refer to a specialist.
    3. Treat patients with NAFLD with an emphasis on modifying their metabolic risk factors that will have an impact on liver disease even in the absence of weight loss.
    4. Identify medications that can be used in the treatment of NAFLD
  • 11:45 AM-12:45 PM - Post-Post-Postpartum Care: Downstream risks of obesity in pregnancy


    Obesity in pregnancy is extremely common and extremely difficult to treat. Furthermore, the downstream effects on mother and child are wide-reaching. As women’s healthcare milieu adapt to less frequent Pap testing, as well as other reductions in face to face care, awareness of these risks and identification of appropriate targets for mitigating risks is essential. This session will review the pregnancy risks associated with obesity and the complicated interplay of associated long-term risks from pregnancy conditions in the setting of long-term risks of obesity alone. Interactive components include generating diagnoses associated with risk, estimating long term risk, and then applying the data to these areas of potential misconception. Participants will leave the session with a better understanding of the complexity of risks as well as an understanding of the long-term multidisciplinary team needs for adequate care of women with obesity who have experienced pregnancy complications.

    Learning Objectives:

    1. List the long-term health risks associated with common pregnancy complications.
    2. Identify the magnitude of increased risks of long-term pregnancy complication with concomitant obesity.
    3. Describe appropriate methods and intervals for long term risk assessment for women with obesity and prior pregnancy complications.
  • 12:45-1:45 PM - Exhibit Hall Break

    Visit the exhibitors and explore the latest technologies, products, and services available to enhance and improve your practice. Meet with exhibitors, try samples, and discover new tools to use when treating patients with obesity.

  • 1:45-2:30 PM - Better Together: Exploring Combination Therapies for Obesity Management

    The regulatory systems that affect obesity are complex and involve both peripheral and central components. Existing therapeutic options for obesity management often target one or more of these underlying mechanisms. The utilization of complementary therapies – an approach commonly used in other metabolic diseases – is an under-researched but evolving field in obesity management. The goal of this session will be to explore the present data for complementary dual or triple therapy in obesity management.

    Learning Objectives:

    1. Recognize the mechanistic differences and potentially complementary pathways for anti-obesity therapies.
    2. Review and evaluate the existing data for combination therapy for pharmacologic and device interventions
    3. Review and evaluate the existing data for combination therapy for surgical interventions.
  • 2:30-4:00 PM - Pharmacology Case Study

    This session will include a series of case presentations exploring medication options in specific patient scenarios. Each scenario presented will explore the different agents that could be used for the patient scenario and the rationale behind why and when certain medications are recommended over others. The program will conclude with an interactive discussion on each of these cases.

    Learning Objectives:

    1. Explore the contributors to obesity in individual patients based upon the clinical presentation.
    2. Identify concurrent medications that may contribute to weight gain or worsen obesity-related disease.
    3. Prescribe or deprescribe medication based upon the clinical case scenario to optimize weight loss and improve or reverse obesity related disease.  

Schedule on Saturday, Oct. 16

All times displayed in Eastern Time (EST)

  • 10:00-11:00 AM - Keynote Speaker: Robert Kushner, MD, MS, FACP, DABOM

    STEP, The First of Many Steps Toward the Future of Obesity Pharmacotherapy

    Robert Kushner, MD, MS, FACP, DABOM

    The Semaglutide Treatment Effect in People with Obesity (STEP) Trials have been described as a game changer for obesity care. In this presentation, Dr. Kushner will review the efficacy and safety outcomes of the 4 STEP trials and their importance for patient care.

    Learning Objectives:

    1. Describe the semaglutide 2.4 mg STEP Trials and key take-aways.
    2. Discuss other emerging pharmacotherapies for obesity.
    3. Explain the importance of the behavior-drug interface.
  • 11:00 AM-12:00 PM - Why did OMA Change the Rules (Body Composition and Physical-activity)?


    The Obesity Medicine Association (OMA) is the clinical leader in obesity medicine.  In its 2021 update, the OMA Obesity Algorithm clarified the role of steps in meeting physical activity recommendations.  OMA also provided guidance regarding cut-off points in body composition analyses.  This session will describe these "rule changes," and provide perspective how it influences the care of patients with obesity.  

    Learning Objectives:

    1. Discuss sentinel changes to the latest OMA Obesity Algorithm
    2. Describe a new classification for percent body fat
    3. Describe a new classification for android and visceral fat
    4. Apply a new classification for physical activity goals
  • 12:00-1:00 PM - Exhibit Hall Break

    Visit the exhibitors and explore the latest technologies, products, and services available to enhance and improve your practice. Meet with exhibitors, try samples, and discover new tools to use when treating patients with obesity.

  • 1:00-2:00 PM - Treating Obesity in the Older Patient

    Older individuals with obesity are at risk for both the metabolic consequences of central abdominal obesity and the adverse effects of fat mass. Identifying obesity in elderly patients may be obscured by loss of lean body mass and adipose redistribution with aging, rendering BMI as a diagnostic marker less reliable. In this population, treatment options are often limited by coexisting medical conditions, lack of evidence for the benefits of obesity treatment interventions, and potential negative effects of weight loss on lean body mass, bone mineral density, and mortality. This lecture will address strategies to improve health and physical function in elderly patients with obesity, while minimizing potential pitfalls.

    Learning objectives:

    1. Describe the consequences of obesity in older patients.
    2. Identifying Obesity in Clinical Practice and the Limits of BMI as a measure in older adults.
    3. Recognize the benefits of weight loss in older adults.
    4. Develop a treatment plan that optimizes health and physical function and minimizes potential adverse consequences of weight loss in elderly individuals.
  • 2:00-3:00 PM - The Influence of Insulin Resistance in Type 2 Diabetes

    Insulin resistance has become the world's most common health disorders and Type 2 Diabetes is recognized as a leading killer in the United States. To understand T2DM, we need to understand insulin resistance, the true foundation of the disease. This talk will provide a basic and clinical definition of insulin resistance and explain the process whereby insulin resistance turns into type T2DM.

    Learning Objectives:

    1. Understand the two pillars of insulin resistance as hyperinsulinemia and compromised insulin signaling.
    2. Learn the role of fat cell hypertrophy in the origins of insulin resistance.
    3. Understand the role of the muscle, liver, and pancreas in the transition into type 2 diabetes from insulin resistance.

Register Now

Commercial Support

This education activity has received commercial support through an educational grant from Rhythm Pharmaceuticals and Ethicon.

Featured Sponsor

Rhythm Pharmaceuticals